sb 202190 has been researched along with Proliferative Vitreoretinopathy in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saika, S | 1 |
| Yamanaka, O | 1 |
| Ikeda, K | 1 |
| Kim-Mitsuyama, S | 1 |
| Flanders, KC | 1 |
| Yoo, J | 1 |
| Roberts, AB | 1 |
| Nishikawa-Ishida, I | 1 |
| Ohnishi, Y | 1 |
| Muragaki, Y | 1 |
| Ooshima, A | 1 |
1 other study available for sb 202190 and Proliferative Vitreoretinopathy
| Article | Year |
|---|---|
Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells.
Topics: Animals; Cell Line; Cell Movement; Cell Proliferation; Collagen Type I; Disease Models, Animal; Enzy | 2005 |